维普中文期刊产品整合服务
105篇 您的检索式:作者名="Prenen"
    题名 作者 年代 出处 被引量
1Differential Protein expression profile in gastrointestinal tumors 显示文摘Landuyt B Prenen H Debiec-Rychter M 2004Amino Acids2004,27,:1
2Voltage dependence of the Ca2+- activated cation channel TRPM4显示文摘Nilius B Prenen J Droogmans G 2003J Biol Chem2003,278,30:1
3TRPV4 calcium entry channel:a paradigm for gating diversity 显示文摘Nilius B Vriens J Prenen J 2004Am J Physiol Cell Physiol2004,286,2:1
4Cellular uptake of the tyrosine kinase inhibitors ima-tinib and AMN107 in gastrointestinal stromal tumor cell lines显示文摘Prenen H 2006Pharmacology2006,77,1:1
5Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines显示文摘PRENEN H GUETENS G BOECK G 2006Pharmacology2006,77,:1
6Whole-cell and single channel monovalent cation currents through the novel rabbit epithelial Ca2+channel显示文摘Nilius B Vennekens R Prenen J 2000J Physiol2000,527,2:1
7Minimally invasive liver surgery for metastases from colorectal cancer: oncologic outcome and prognostic factors显示文摘Baki Topal Joyce Tiek Steffen Fieuws Raymond Aerts Eric Cutsem Tania Roskams Hans Prenen 2012Surgical Endoscopy2012,,8:1
8TRPV channels and modula-tion by hepatocyte growth factor/scatter factor in human hepatoblas-toma(HepG2)cells显示文摘Vriens J Janssens A Prenen J 2004Cell Calcium2004,36,33:1
9PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer显示文摘PRENEN H DE SCHUTTER J JACOBS B 2009Clin Cancer Res2009,15,9:1
10Efficacy of the Kinase inhibiter SU 11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate 显示文摘Prenen H Cools J Mentens N 2006Clin Cancer Res2006,12,26:1
11Permeation and gating properties of the novel epithelial Ca(2+) channel显示文摘Vennekens R Hoenderop JG Prenen J 2000J Biol Chem2000,275,6:1
12TRPV4 calcium entry channel: a paradigm for gating diversity显示文摘Nilius B Vriens J Prenen J 2004Am J Physiol Cell Physio12004,286,2:1
13Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography显示文摘Prenen H Deroose C Vermaelen P 2006Anticancer Res2006,26,2:1
14Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients显示文摘Maertens O Prenen H Debiec-Rychter M 2006Hum Mol Genet2006,15,:1
15Molecular genetics of colorectal cancer显示文摘Bogaert J Prenen H 2014Ann Gastroenterol2014,27,1:1
16Intrahepatic therapy for liver-dominant metastatic colorectal cancer显示文摘In patients with metastatic colorectal cancer, the liver is the most common site of metastatic disease. In patients with liver-dominant disease, consideration needs to be given to locoregional treatments such as hepatic arterial infusion chemotherapy, transarterial chemoembolisation and selective internal radiation therapy because hepatic metastases are a major cause of liver failure especially in chemorefractory disease. In this review we provide insights on the published literature for locoregional treatment of liver metastases in metastatic colorectal cancer.Kerlijne De Groote Hans Prenen 2015World Journal of Gastrointestinal Oncology2015,7,9:1
17Sensitive and specif- ic quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatogra- phy-tandem mass spectrometry 显示文摘Guetens G Prenen H De Boeck G 2005J Chromatogr A2005,1082,1:1
18Intracellular nueleotides and polyarnines inhibit the Ca2+-activated cation channel TRPM4b 显示文摘Nilius B Prenen J Voets T 2004Pflugers Arch2004,448,:1
19Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate 显示文摘Prenen H Cools J Mentens N 2006Clin Cancer Res2006,12,8:1
20Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refactory to imatinib mesylate显示文摘Prenen H Cools J Mentens N 2006Clin Cancer Res2006,12,20:1
返回顶部 每页显示:
共6页 首页 上一页 第1页 下一页 末页 /6 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费